💨 Abstract
A recent study suggests that fluvoxamine, a common antidepressant, significantly improves fatigue and quality of life in adults with long COVID. The trial, involving 399 participants, showed a 99% probability that fluvoxamine outperformed a placebo. The drug's anti-inflammatory properties are believed to reduce inflammation, alleviating fatigue. However, experts call for more research to distinguish between long COVID and depression, as fatigue is a symptom of both.
Courtesy: Adriana Fallico
Suggested
Trump says ‘a whole civilization will die tonight’ as Iran deadline looms - National Globalnews.ca
Aircraft runway incursions rise in Canada, but one key metric levels off - National Globalnews.ca
Artemis II is about to fly past the moon and is set to break records - National Globalnews.ca
From ‘bird leg syndrome’ to solar storms: Roberta Bondar breaks down Artemis II mission - National Globalnews.ca
Iran calls on the public to find the ‘enemy pilot’ as the US continues a frantic search - National Globalnews.ca
Canadian Space Agency’s first space to Earth video call with Colonel Jeremy Hansen - National Globalnews.ca
Canadian faces terrorism charge after machete attack on mosque in Kenya - National Globalnews.ca
Ottawa proposes making it easier to share personal data among government - National Globalnews.ca
Long weekend gas prices likely to climb as Iran war fuels energy crunch - National Globalnews.ca